Archive | Publications

The State of Melanoma: Emergent Challenges and Opportunities

Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications

FDA Grants Orphan Drug Designation to Novel Immunotherapy in Advanced Melanoma

The FDA has granted an Orphan Drug designation to the novel immunotherapy PVSRIPO for the treatment of patients with advanced melanoma of stage IIB-IV, Istari Oncology, Inc., announced in a press release.1

Read the full story

Posted in Melanoma News, Regulatory, Publications

Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

In this single-arm, phase II trial, researchers sought to evaluate the effectiveness of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival

Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) and venous TE (VTE) in patients with melanoma on immune checkpoint inhibitor (ICI) therapy.

Read the full story

Posted in Melanoma News, Publications, Scientific Publications